Chinese Clinical Oncology

• 综述与讲座 • Previous Articles     Next Articles

Progress of resistance mechanism of oxaliplatin on hepatocellular carcinoma

ZHENG Meiling,HUA Haiqing   

  1. Cancer Center of PLA,81 Hospital Affiliated to Nangjing University of Chinese Medicine,Nangjing 210002,China
  • Received:2017-01-22 Revised:2017-02-21 Online:2017-04-30 Published:2017-04-30
  • Contact: HUA Haiqing

Abstract:

Oxaliplatin has been approved for the treatment of advanced hepatocellular carcinoma(HCC)in China. FOLFOX4 regimen based on oxaliplatin has become one of the standard treatments for advanced HCC,which can significantly prolong the survival of patients with HCC,and also show good safety and tolerance. However,the clinical efficacy of oxaliplatin on HCC is very limited. The treatment failure is closely related to the resistance of HCC. This article reviews the progress about current researches on the resistance mechanism of oxaliplatin in the treatment of HCC,arming to help clinical and scientific researchers to understand the latest development,and to broaden their thinking in future work.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!